Trust Company of Vermont’s Moderna MRNA Stock Holding History

Trust Company of Vermont’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.9K	Buy	+255	New	+$13.2K	﹤0.01%	810
2025 Q4	$4.42K	Hold	150	–	–	﹤0.01%	956
2025 Q3	$3.88K	Hold	150	–	–	﹤0.01%	953
2025 Q2	$4.14K	Hold	150	–	–	﹤0.01%	947
2025 Q1	$4.25K	Hold	150	–	–	﹤0.01%	867
2024 Q4	$6.24K	Sell	150 -300	-67%	-$14.3K	﹤0.01%	825
2024 Q3	$30.1K	Sell	450 -50	-10%	-$4.59K	﹤0.01%	592
2024 Q2	$59.4K	Hold	500	–	–	﹤0.01%	469
2024 Q1	$53.3K	Hold	500	–	–	﹤0.01%	481
2023 Q4	$49.7K	Hold	500	–	–	﹤0.01%	431
2023 Q3	$51.6K	Hold	500	–	–	﹤0.01%	453
2023 Q2	$60.8K	Hold	500	–	–	﹤0.01%	463
2023 Q1	$76.8K	Hold	500	–	–	0.01%	427
2022 Q4	$89.8K	Hold	500	–	–	0.01%	399
2022 Q3	$59K	Hold	500	–	–	﹤0.01%	465
2022 Q2	$71K	Buy	+500	New	+$71.5K	0.01%	432
2022 Q1	–	Sell	-500	Closed	-$127K	–	592
2021 Q4	$127K	Buy	+500	New	+$146K	0.01%	370
2021 Q3	–	Sell	-500	Closed	-$117K	–	569
2021 Q2	$117K	Hold	500	–	–	0.01%	378
2021 Q1	$65K	Buy	500 +60	+14%	+$8.7K	﹤0.01%	436
2020 Q4	$46K	Hold	440	–	–	﹤0.01%	458
2020 Q3	$31K	Buy	440 +300	+214%	+$20.9K	﹤0.01%	484
2020 Q2	$9K	Buy	+140	New	+$7.67K	﹤0.01%	636

Other funds holding MRNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Trust Company of Vermont's MRNA Position: Q2 2026 in Review

Trust Company of Vermont opened a new position in Moderna (MRNA) in Q2 2026: 255 shares worth $17.9K. The stake represents ﹤0.01% of the portfolio and ranks #810 among its holdings. This is a return to the name: Trust Company of Vermont previously reported a position in MRNA as recently as Q4 2025.

Trust Company of Vermont first reported a position in MRNA in Q2 2020 and has held it in 22 quarters since. The position peaked at $127K in Q4 2021. 385 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Trust Company of Vermont held 255 shares of Moderna worth $17.9K as of Q2 2026.
Moderna was a new Trust Company of Vermont position in Q2 2026.
Moderna made up ﹤0.01% of Trust Company of Vermont's portfolio in Q2 2026, its #810 holding.
Trust Company of Vermont first reported a position in Moderna in Q2 2020 and has held it in 22 quarters since.
Trust Company of Vermont's Moderna position peaked at $127K in Q4 2021.
385 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Trust Company of Vermont's 13F filing for Q2 2026, filed 7 Aug 2026.